Home › Overweight › Tennessee
Overweight clinical trials in Tennessee
24 studies for Overweight are looking for participants at sites in Tennessee.
Cities in Tennessee
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Innovative Clinical Research, Clarksville
- Clinical Research Associates, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07351045A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Franklin
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07776509A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
- Clinical Research Associates, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07843498A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- New Phase Research and Development, Knoxville
- Clinical Research Associates Inc, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07794579A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- DelRicht Research - Thompson's Station, Smyrna
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06857942Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastroenterology Center Of The Midsouth, Cordova
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Nov 4, 2026 · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastroenterology Center Of The Midsouth, Cordova
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Nov 4, 2026 · NCT06937086A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Vanderbilt Health One Hundred Oaks, Nashville
RecruitingPhase 3
Ages 6 to 17 · All sexes · Updated Nov 4, 2026 · NCT06672549Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
- Alliance for Multispecialty Research - Knoxville, Knoxville
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Nov 2, 2026 · NCT07908316A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Kingsport
- Research Site, Memphis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07784725A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Franklin
- Research Site, Jackson
- Research Site, Knoxville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT07784270Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Holston Medical Group - Bristol /ID# 282045, Bristol
- New Phase Research & Development /ID# 282131, Knoxville
- Summit Medical Group- Halls Family Physicians /ID# 282435, Knoxville
- and 1 more
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 27, 2026 · NCT07752979Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- AMR Clinical, Nashville
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 26, 2026 · NCT07837973A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Nashville
RecruitingPhase 3Healthy volunteers welcome
Ages 18 to 79 · All sexes · Updated Oct 20, 2026 · NCT07654374Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
- Holston Medical Group_Bristol, Bristol
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT07607587A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Quality Medical Research, Nashville
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 8, 2026 · NCT07589608A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Quality Medical Research, Nashville
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 7, 2026 · NCT06143956Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- New Phase Research and Development, Knoxville
- Accellacare US Inc., d/b/a Accellacare of Knoxville, Knoxville
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Oct 5, 2026 · NCT07684235A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- LifeDoc Health, Memphis
RecruitingPhase 3
Ages 8 to 18 · All sexes · Updated Sep 30, 2026 · NCT07253285A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- AMR Clinical, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07321886A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Memphis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07743450A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Memphis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07743463Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Knoxville
RecruitingPhase 3
Ages 18 to 79 · All sexes · Updated Aug 10, 2026 · NCT07654361A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
- MBX Biosciences Investigational Site, Knoxville
RecruitingPhase 1
Ages 18 to 65 · All sexes · Updated Jun 9, 2026 · NCT07142707From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.